Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2008

View Archived Issues

Novel microtubule-stabilizing drug improves neurofibrillary Tau pathology in vitro and in vivo

Novel NMDA receptor modulator shows neuroprotection against ethanol withdrawal, consumption

Novel therapeutic agents for cardiovascular disorders imparted in recent patent literature

Sanofi-aventis reports preclinical data of novel trioxaquine candidate for malaria

Long-term retreatment of HBV patients with entecavir effective

Multiple doses of MK-7009 safe in HCV patients

Oncolytics Biotech presents clinical results with its novel oncolytic reovirus type 3 Dearing

New neuropsychiatric agents reported

Recent Daiichi Sankyo patent discloses novel antithrombotic agents

EMEA recommends the suspension of the marketing authorization of Ionsys

Moberg reports results from phase III clinical study of K-101 for nail fungus

Resolvyx to initiate phase I/II clinical trial of RX-10045 in moderate to severe dry eye

European Commission withdraws Schering-Plough's marketing authorization for Viraferon

Lilly completes cash tender offer for ImClone Systems

Aeolus initiates animal study of AEOL-10150 in damage to the lungs due to radiation

CHMP recommends approval of Enbrel for severe plaque psoriasis in pediatric patients

Genentech and Roche report results from RIBBON 1 phase III clinical study of Avastin

FDA grants pralatrexate orphan drug status for diffuse large B-cell lymphoma

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

CHMP issues positive opinion for Stelara in plaque psoriasis

Essentialis completes patient enrollment in phase II DCCR trial

Factor IXFc receives FDA orphan drug status for hemophilia B

FDA accepts DX-88 filing and grants priority review for hereditary angioedema

Valdoxan receives CHMP positive opinion for major depressive disorder

Xenazine tablets available in U.S. for chorea associated with HD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...